We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ra Pharmaceuticals Inc | NASDAQ:RARX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 47.995 | 40.00 | 50.00 | 0 | 01:00:00 |
Ra Pharmaceuticals, Inc., (NASDAQ:RARX), a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases, today announced that Doug Treco, PhD, President and Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 11:20 a.m. E.T. The conference is being held at the Boston Marriott Copley Place.
The presentation will be webcast live and can be accessed by visiting the investor relations section of the Company’s website, www.rapharma.com. A replay of the presentation will also be available and archived on the site for three weeks.
About Ra Pharmaceuticals
Ra Pharmaceuticals is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for complement-mediated diseases. The Company discovers and develops peptides and small molecules to target key components of the complement cascade. For more information, please visit: www.rapharma.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170301005376/en/
Ra Pharmaceuticals, Inc.Investors:Jennifer Robinson, 617.674.9873jrobinson@rapharma.comorMedia:Argot PartnersEliza Schleifstein, 917.763.8106eliza@argotpartners.com
1 Year Ra Pharmaceuticals Chart |
1 Month Ra Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions